| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 65 | 23.9x | 17.8x | Around median | |
Growth | 64 | 5.1% | 7.1% | Around median | |
Quality | 74 | 14.4% | 4.5% | Top tier | |
Safety | 64 | 1.3x | 2.6x | Around median | |
Capital Return | 30 | 0.73% | 2.12% | Bottom tier | |
Momentum | 50 | 9.6% | 2.9% | Around median | |
Sentiment | 82 | 10 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Cencora operates in pharmaceutical product distribution and the provision of related services to healthcare providers and manufacturers. The U.S. Healthcare Solutions segment generated $74.9 billion in revenue in fiscal Q3 2026 from U.S. distribution and specialty pharmaceutical services for hospitals and physician practices, including practice management organization services and the OneOncology and RCA platforms. The International Healthcare Solutions segment added $7.7 billion in revenue from European distribution and specialty logistics through World Courier and European 3PL services, while activities classified under Other, including Profarma and MWI Animal Health, recorded $2.3 billion in revenue.
Cencora's revenue in fiscal Q3 2026 reached approximately $84.8 billion, up 5%, and gross profit according to EDGAR filings was approximately $3.6 billion, while net income was $763.5 million and earnings per share were $3.94. On the adjusted basis presented by management, gross profit was $3.5 billion and its margin expanded by 61 basis points to 4.16%, while adjusted operating income rose 17% to $1.2 billion and adjusted earnings per share grew 12%.
U.S. Healthcare Solutions accounted for approximately 88% of fiscal Q3 2026 revenue, and its operating income rose 16% to $966 million, compared with $166 million for the international segment, up 21%, and $109 million for Other activities, up 25%. For the twelve months ended within the 2026 data, the company recorded revenue of $328.7 billion and net income of $2.5 billion, compared with revenue of $321.3 billion and net income of $1.6 billion in fiscal 2025.
The average analyst price target is $358.14, within a wide range of $330 to $430, with a Buy consensus; the average is below the 52-week range high of $377.54, while the highest target exceeds that high. In contrast, the GF Value model estimated fair value at $293.51 on August 5, 2026, revealing a significant divergence between the automated valuation and analyst consensus, and the available data does not include a valid price-to-earnings ratio that can be used to confirm either valuation.
Figures in the text are as of 2026-08-27; the live price is shown at the top of the page.
Revenue reached $84.8 billion, up 5%, and the company recorded net income of $763.5 million and earnings per share of $3.94 according to EDGAR data. On an adjusted basis, operating income rose 17% to $1.2 billion and earnings per share grew 12%. Performance was driven primarily by specialty pharmaceutical growth across health systems and physician practices, along with OneOncology and RCA exceeding management's expectations.
The two platforms provide services to oncology and retinal practices and connect those practices with Cencora's distribution, group purchasing, and pharmaceutical service capabilities. In fiscal Q3 2026, management said both platforms performed above expectations and that OneOncology generated operating income modestly better than initial estimates. The company expects OneOncology to remain neutral to adjusted earnings per share on a twelve-month basis after accounting for financing, while it sees additional opportunities in clinical trials, analytics, and physician additions.
GLP-1 sales increased by $2.3 billion year over year, or approximately 25%, in fiscal Q3 2026, which was generally in line with management's expectations. Cencora believes Part B biosimilars offer a greater earnings opportunity because they combine distribution, group purchasing, and support services for physicians and manufacturers. Part D biosimilars remain positive to a lesser degree and could create revenue pressure if a mail-order customer brings some activities back in-house.
Automated analysis for informational purposes only — not investment advice.
The company raised its adjusted earnings per share guidance to a range of $17.75–$17.95, compared with $17.70–$17.90 previously. It expects consolidated operating income growth of between 13% and 14%, and operating income growth of between 14.5% and 15.5% for the U.S. Healthcare Solutions segment. It also maintained adjusted free cash flow guidance at approximately $3 billion, but expects U.S. segment revenue growth to fall within the lower half of the 4%–6% range.
As of August 5, 2026, Cencora was still evaluating changes to the 340B test and ASP proposals and had not provided a quantitative estimate of their potential impact on community practices or practice management organizations. Financially, debt from the OneOncology acquisition increased net interest expense to $141 million in fiscal Q3 2026, up $59 million year over year, despite the full repayment of the $800 million RCA loan. The completion of the combination of MWI Animal Health with Covetrus in the middle of fiscal 2027, under management's assumption, could also have a net negative impact of approximately $0.35 on earnings per share.
The analyst consensus is Buy, with an average price target of $358.14, a low target of $330, and a high target of $430. The average target is below the 52-week range high of $377.54, while the highest target exceeds it. In contrast, the GF Value model estimated fair value at $293.51 on August 5, 2026, so the data reflects a clear divergence between the value model and analyst consensus.
